<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618241</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 07.06</org_study_id>
    <nct_id>NCT00618241</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study on Raltegravir and Lamotrigine</brief_title>
  <acronym>GRANOLA</acronym>
  <official_title>The Influence of Raltegravir (MK-0518) on the Pharmacokinetics of Single-dose Lamotrigine in Healthy Male Subjects (GRANOLA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether interactions between raltegravir and
      lamotrigine take place and to study the safety of the combination raltegravir/lamotrigine
      before used in HIV patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lamotrigine is an anticonvulsive drug that is used both for the treatment of HIV-associated
      neuropathic pain and the treatment of epilepsy in HIV-infected individuals. Lamotrigine is
      metabolized via glucuronidation.

      Raltegravir is a newly developed integrase inhibitor that is also metabolized via
      glucuronidation.

      Since both agents are metabolized via glucuronidation, there is a possibility of competition
      for glucuronidation, leading to drug-drug interactions between raltegravir and lamotrigine.

      This primary objective of this study is to determine the effect of raltegravir on the
      pharmacokinetics of single dose lamotrigine (by intrasubject comparison). A secondary
      objective is to determine the effect of single dose lamotrigine on the pharmacokinetics of
      raltegravir when compared to historical controls. Another secondary objective is to evaluate
      the safety of combined use of single dose lamotrigine and raltegravir.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of lamotrigine, lamotrigine-2N-glucuronide, and raltregravir</measure>
    <time_frame>just before dosing, at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 24 hours and 48 hours after dosing on study days 4-5 and 32-33.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters (AUC, Cmax, Tmax, Cmin and T 1/2) by noncompartmental analysis</measure>
    <time_frame>at each sampling time</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.
5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.
One dose Lamotrigine 100 mg oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine</intervention_name>
    <description>100 mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg BD</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55 years of age

          -  Subject does not smoke more than 10 cigarettes, 2 cigars or 2 pipes per day

          -  Subject has a Quetelet Index of 18 to 30 kg/m2

          -  Subject is able and willing to sign informed consent

          -  Subject is in good age-appropriate health condition

          -  Subject has a normal blood pressure and pulse rate

        Exclusion Criteria:

          -  History of sensitivity/idiosyncrasy to medicinal products or excipients

          -  Positive HIV test

          -  Positive hepatitis B or C test

          -  Therapy with any drug (2 weeks preceding dosing) except for paracetamol

          -  Relevant history or presence of pulmonary disorders, cardiovascular

          -  History of or current abuse of drugs, alcohol or solvents

          -  Inability to understand the nature and extent of the trial and procedures

          -  Participation in a drug trial within 60 days prior to the first dose

          -  Donation of blood within 60 days prior to the first dose

          -  Febrile illness within 3 days before the first dose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Burger, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19717722?dopt=Citation</url>
    <description>Results published in The Journal of Clinical Pharmacology; 2009; 49; 1220</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2008</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. D.M. Burger, hospital pharmacist</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>interactions</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

